Skip to main content
Top
Published in: Intensive Care Medicine 3/2009

01-03-2009 | Original

Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients

Authors: José A. Martínez, Esther Delgado, Sara Martí, Francesc Marco, Jordi Vila, Josep Mensa, Antoni Torres, Carles Codina, Antoni Trilla, Alex Soriano, Aitor Alquezar, Pedro Castro, José M. Nicolás

Published in: Intensive Care Medicine | Issue 3/2009

Login to get access

Abstract

Objective

To assess the role of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance.

Design

Prospective cohort study.

Setting

Two medical intensive care units.

Patients and participants

346 patients admitted for ≥ 48 h.

Intervention

Analysis of data from an 8-month study comparing a mixing versus a cycling strategy of antibiotic use.

Measurements and results

Surveillance cultures from nares, pharynx, rectum, and respiratory secretions were obtained thrice weekly. Acquisition of resistance was defined as the isolation, after 48 h of ICU stay, of an isolate resistant to a given antibiotic if culture of admission samples were either negative or positive for a susceptible isolate. Emergence of resistance refers to the conversion of a defined pulsotype from susceptible to non-susceptible. Forty-four (13%) patients acquired 52 strains of P. aeruginosa. Administration of piperacillin-tazobactam for ≥ 3 days (OR 2.6, 95% CI 1.09–6.27) and use of amikacin for ≥ 3 days (OR 2.6, 95% CI 1.04–6.7) were positively associated with acquisition of P. aeruginosa, whereas use of quinolones (OR 0.27, 95% CI 0.1–0.7) and antipseudomonal cephalosporins (OR 0.27, 95% CI 0.08–0.9) was protective. Exposure to quinolones and cephalosporins was not associated with the acquisition of resistance, whereas it was linked with usage of all other agents. Neither quinolones nor cephalosporins were a major determinant on the emergence of resistance to themselves, as resistance to these antibiotics developed at a similar frequency in non-exposed patients.

Conclusions

In critically ill patients, quinolones and antipseudomonal cephalosporins may prevent the acquisition of P. aeruginosa and may have a negligible influence on the acquisition and emergence of resistance.
Literature
1.
2.
go back to reference Bonten MJM, Bergmans DCJJ, Speijer H, Stobberingh EE (1999) Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control. Am J Respir Crit Care Med 160:1212–1219PubMed Bonten MJM, Bergmans DCJJ, Speijer H, Stobberingh EE (1999) Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control. Am J Respir Crit Care Med 160:1212–1219PubMed
3.
go back to reference Lepelletier D, Caroff N, Riochet D, Bizouarn P, Bourdeau A, Le Gallou F, Esparze E, Reynaud A, Richet H (2006) Role of hospital stay and antibiotic use on Pseudomonas aeruginosa gastrointestinal colonization in hospitalized patients. Eur J Clin Microbiol Infect Dis 25:600–603PubMedCrossRef Lepelletier D, Caroff N, Riochet D, Bizouarn P, Bourdeau A, Le Gallou F, Esparze E, Reynaud A, Richet H (2006) Role of hospital stay and antibiotic use on Pseudomonas aeruginosa gastrointestinal colonization in hospitalized patients. Eur J Clin Microbiol Infect Dis 25:600–603PubMedCrossRef
4.
go back to reference Rello J, Ausina V, Ricart M, Castella J, Prats G (1993) Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104:1230–1235PubMedCrossRef Rello J, Ausina V, Ricart M, Castella J, Prats G (1993) Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 104:1230–1235PubMedCrossRef
5.
go back to reference Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531–539PubMed Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531–539PubMed
6.
go back to reference Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999) Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43:1379–1382PubMed Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999) Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43:1379–1382PubMed
7.
go back to reference Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RL, Harverstock DC, Reinhart HH, Echols RM, the Severe Pneumonia Study Group (1994) Treatment of severe pneumonia in hospitalizae patients: result of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 38:547–557PubMed Fink MP, Snydman DR, Niederman MS, Leeper KV, Johnson RH, Heard SO, Wunderink RG, Caldwell JW, Schentag JJ, Siami GA, Zameck RL, Harverstock DC, Reinhart HH, Echols RM, the Severe Pneumonia Study Group (1994) Treatment of severe pneumonia in hospitalizae patients: result of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 38:547–557PubMed
8.
go back to reference Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Cometta A, The Cefepime Study Group (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442–3447PubMedCrossRef Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Cometta A, The Cefepime Study Group (2003) Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 47:3442–3447PubMedCrossRef
9.
go back to reference Troillet N, Samore MH, Carmeli Y (1997) Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 25:1094–1098PubMedCrossRef Troillet N, Samore MH, Carmeli Y (1997) Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 25:1094–1098PubMedCrossRef
10.
go back to reference El Amari EB, Chamot E, Auckenthaler R, Pechère JC, Van Delden C (2001) Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 33:1859–1864PubMedCrossRef El Amari EB, Chamot E, Auckenthaler R, Pechère JC, Van Delden C (2001) Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 33:1859–1864PubMedCrossRef
11.
go back to reference Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC (2002) Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 34:340–345PubMedCrossRef Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC (2002) Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 34:340–345PubMedCrossRef
12.
go back to reference Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA (2002) Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 46:854–858PubMedCrossRef Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA (2002) Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 46:854–858PubMedCrossRef
13.
go back to reference Paladino JA, Sunderlin JL, Forrest A, Schentag JJ (2003) Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52:457–463PubMedCrossRef Paladino JA, Sunderlin JL, Forrest A, Schentag JJ (2003) Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52:457–463PubMedCrossRef
14.
go back to reference Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A (2005) Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55:535–541PubMedCrossRef Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A (2005) Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 55:535–541PubMedCrossRef
15.
go back to reference Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68–74PubMedCrossRef Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2005) Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 11:68–74PubMedCrossRef
16.
go back to reference Ozkurt Z, Erteck M, Ero S, Altoparlak U, Akcay MN (2005) The risk for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burn 31:870–873CrossRef Ozkurt Z, Erteck M, Ero S, Altoparlak U, Akcay MN (2005) The risk for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burn 31:870–873CrossRef
17.
go back to reference Zavascki AP, Cruz RP, Goldani LZ (2005) Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparitive analysis of two case-control studies in hospitalized patients. J Hosp Infect 59:96–101PubMedCrossRef Zavascki AP, Cruz RP, Goldani LZ (2005) Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparitive analysis of two case-control studies in hospitalized patients. J Hosp Infect 59:96–101PubMedCrossRef
18.
go back to reference Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M (2006) Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 27:901–906PubMedCrossRef Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M (2006) Risk factors for recovery of imipenem- or ceftazidime-resistant Pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect Control Hosp Epidemiol 27:901–906PubMedCrossRef
19.
go back to reference Gasink LB, Fishman NO, Weiner MG, Nachmkin I, Bilker WB, Lautehnbach E (2006) Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 119:526.e19–526.e25CrossRef Gasink LB, Fishman NO, Weiner MG, Nachmkin I, Bilker WB, Lautehnbach E (2006) Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 119:526.e19–526.e25CrossRef
20.
go back to reference Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y (2006) Differential efects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:2192–2196PubMedCrossRef Kaye KS, Kanafani ZA, Dodds AE, Engemann JJ, Weber SG, Carmeli Y (2006) Differential efects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:2192–2196PubMedCrossRef
21.
go back to reference Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J (2007) Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 51:1967–1971PubMedCrossRef Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J (2007) Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother 51:1967–1971PubMedCrossRef
22.
go back to reference Arruda EAG, Marinho IS, Boulos M, Sinto SI, Caiaffa HH, Mendes CM, Oplustil CP, Sader H, Levy CE, Levin AS (1999) Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 20:620–623PubMedCrossRef Arruda EAG, Marinho IS, Boulos M, Sinto SI, Caiaffa HH, Mendes CM, Oplustil CP, Sader H, Levy CE, Levin AS (1999) Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 20:620–623PubMedCrossRef
23.
go back to reference Cao B, Wang H, Sun H, Zhu Y, Chen M (2004) Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 57:112–118PubMedCrossRef Cao B, Wang H, Sun H, Zhu Y, Chen M (2004) Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 57:112–118PubMedCrossRef
24.
go back to reference Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP, Sotto A (2004) Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 57:209–216PubMedCrossRef Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP, Sotto A (2004) Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect 57:209–216PubMedCrossRef
25.
go back to reference Lauthenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO (2006) Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infec Control Hosp Epidemiol 27:893–900CrossRef Lauthenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO (2006) Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infec Control Hosp Epidemiol 27:893–900CrossRef
26.
go back to reference Lee SC, Fung CP, Liu PYF, Wang TC, See LC, Lee N, Chen SC, Shieh WB (1999) Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome. Infect Control Hosp Epidemiol 20:205–207PubMedCrossRef Lee SC, Fung CP, Liu PYF, Wang TC, See LC, Lee N, Chen SC, Shieh WB (1999) Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk factors and outcome. Infect Control Hosp Epidemiol 20:205–207PubMedCrossRef
27.
go back to reference Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, Dvorak T, Hogan H, Hachem R, Rolston K, Raad I (2005) Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104:205–212PubMedCrossRef Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, Dvorak T, Hogan H, Hachem R, Rolston K, Raad I (2005) Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104:205–212PubMedCrossRef
28.
go back to reference Ortega B, Groeneveld ABJ, Schultsz C (2004) Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epìdemiol 25:825–831PubMedCrossRef Ortega B, Groeneveld ABJ, Schultsz C (2004) Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epìdemiol 25:825–831PubMedCrossRef
29.
go back to reference Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomoal activity. Clin Infect Dis 38:670–677PubMedCrossRef Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A (2004) Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomoal activity. Clin Infect Dis 38:670–677PubMedCrossRef
30.
go back to reference Philippe E, Weiss M, Schultz JM, Yeomans F, Ehrenkranz NJ (1999) Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 7:83–87PubMed Philippe E, Weiss M, Schultz JM, Yeomans F, Ehrenkranz NJ (1999) Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 7:83–87PubMed
31.
go back to reference Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34:1047–1054PubMedCrossRef Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34:1047–1054PubMedCrossRef
32.
go back to reference Martinez JA, Nicolas JM, Marco F, Horcajada JP, Garcia-Segarra G, Trilla A, Codina C, Torres A, Mensa J (2006) Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 34:329–336PubMedCrossRef Martinez JA, Nicolas JM, Marco F, Horcajada JP, Garcia-Segarra G, Trilla A, Codina C, Torres A, Mensa J (2006) Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 34:329–336PubMedCrossRef
33.
go back to reference Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement (2006) Document M100-S16. Wayne, Pennsylvania Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement (2006) Document M100-S16. Wayne, Pennsylvania
34.
go back to reference Gautom RK (1997) Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 35:2977–2980PubMed Gautom RK (1997) Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 35:2977–2980PubMed
35.
go back to reference Bonten MJM, Slaugther S, Ambergen AW, Hayden MK, von Voorhis J, Nathan C, Weinstein RA (1998) The role of “colonization pressure” in the spread of vancomycin-resistant enterococci. Arch Intern Med 158:1127–1132PubMedCrossRef Bonten MJM, Slaugther S, Ambergen AW, Hayden MK, von Voorhis J, Nathan C, Weinstein RA (1998) The role of “colonization pressure” in the spread of vancomycin-resistant enterococci. Arch Intern Med 158:1127–1132PubMedCrossRef
36.
go back to reference Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedCrossRef
37.
go back to reference Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB (2004) Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39:497–503PubMedCrossRef Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB (2004) Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39:497–503PubMedCrossRef
38.
go back to reference Schwaber MJ, Cosgrove SE, Gold HS, Kaye KS, Carmeli Y (2004) Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens. Em Infect Dis 10:94–99 Schwaber MJ, Cosgrove SE, Gold HS, Kaye KS, Carmeli Y (2004) Fluoroquinolones protective against cephalosporin resistance in gram-negative nosocomial pathogens. Em Infect Dis 10:94–99
39.
go back to reference Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P (1999) In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressin the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 43:287–291PubMed Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P (1999) In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressin the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 43:287–291PubMed
40.
go back to reference Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149–158PubMedCrossRef Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME (2005) Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41:149–158PubMedCrossRef
Metadata
Title
Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients
Authors
José A. Martínez
Esther Delgado
Sara Martí
Francesc Marco
Jordi Vila
Josep Mensa
Antoni Torres
Carles Codina
Antoni Trilla
Alex Soriano
Aitor Alquezar
Pedro Castro
José M. Nicolás
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Intensive Care Medicine / Issue 3/2009
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-008-1326-y

Other articles of this Issue 3/2009

Intensive Care Medicine 3/2009 Go to the issue